Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands

[1]  M. Raethke,et al.  Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature , 2023, Frontiers in Immunology.

[2]  E. V. van Puijenbroek,et al.  Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience , 2022, Drug Safety.

[3]  A. Borobia,et al.  Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial , 2022, The Lancet Infectious Diseases.

[4]  T. Shimabukuro,et al.  Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5–11 Years — United States, May 17–July 31, 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[5]  P. Blanc,et al.  Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[6]  D. Asch,et al.  Comparability of clinical trials and spontaneous reporting data regarding COVID-19 vaccine safety , 2022, Scientific Reports.

[7]  V. Libri,et al.  Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial , 2022, The Lancet Respiratory Medicine.

[8]  J. Haughney,et al.  Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial , 2022, The Lancet Infectious Diseases.

[9]  C. Steves,et al.  COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study , 2022, The Lancet Infectious Diseases.

[10]  P. Dormitzer,et al.  Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine , 2022, The New England journal of medicine.

[11]  F. van Hunsel,et al.  Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands , 2022, Drug Safety.

[12]  T. Shimabukuro,et al.  Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years — United States, December 9, 2021–February 20, 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[13]  D. Montefiori,et al.  Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial , 2022, Nature Medicine.

[14]  E. Woo,et al.  Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[15]  D. Montefiori,et al.  Homologous and Heterologous Covid-19 Booster Vaccinations , 2022, The New England journal of medicine.

[16]  J. Aronson,et al.  Spontaneous Reporting to Regulatory Authorities of Suspected Adverse Drug Reactions to COVID-19 Vaccines Over Time: The Effect of Publicity , 2022, Drug Safety.

[17]  L. Härmark,et al.  COVID-19 vaccine reactogenicity – A cohort event monitoring study in the Netherlands using patient reported outcomes , 2022, Vaccine.

[18]  Scott M Elliott,et al.  Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial , 2021, The Lancet.

[19]  M. Makris,et al.  Vaccine-induced immune thrombotic thrombocytopenia , 2021, The Lancet Haematology.

[20]  Nguyen H. Tran,et al.  Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) , 2021, The Lancet.

[21]  D. Shay,et al.  COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[22]  C. von Kalle,et al.  Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study , 2021, The Lancet Respiratory Medicine.

[23]  B. Gärtner,et al.  Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination , 2021, Nature Medicine.

[24]  S. Ladhani,et al.  Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[25]  A. Borobia,et al.  Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial , 2021, The Lancet.

[26]  F. Kirchhoff,et al.  Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity , 2021, medRxiv.

[27]  P. Moss,et al.  Extended interval BNT162b2 vaccination enhances peak antibody generation in older people , 2021, medRxiv.

[28]  M. Snape,et al.  Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data , 2021, The Lancet.

[29]  C. Murray,et al.  The Potential Future of the COVID-19 Pandemic: Will SARS-CoV-2 Become a Recurrent Seasonal Infection? , 2021, JAMA.

[30]  Nguyen H. Tran,et al.  Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials , 2021, The Lancet.

[31]  Nguyen H. Tran,et al.  Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. , 2020, Lancet.

[32]  M. Alomar,et al.  Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future , 2020, Therapeutic advances in drug safety.

[33]  E. V. van Puijenbroek,et al.  Insight into the Severity of Adverse Drug Reactions as Experienced by Patients , 2019, Drug Safety.

[34]  N. Hartnell,et al.  Replication of the Weber Effect Using Postmarketing Adverse Event Reports Voluntarily Submitted to the United States Food and Drug Administration , 2004, Pharmacotherapy.

[35]  Z. Bánkowski.  Council for International Organizations of Medical Sciences , 2019, Cobert's Manual of Drug Safety and Pharmacovigilance.